GlassScriptPhysician profile
Alfredo Aguirre
NPI 1841296654
$2,301.85
in general payments reported to CMS, 2019-2025
21 companies · $569 in 2025
The $569 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $77.93 · 2021: $56.91 · 2022: $247 · 2023: $464 · 2024: $497 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,531.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $363.85 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $307.23 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Corium, LLC | $271.79 | 2022-2024 | Azstarys |
| Neurocrine Biosciences, INC. | $264.22 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $193.07 | 2019-2025 | Spravato, Invega |
| Alkermes, INC. | $152.47 | 2019-2020 | |
| Indivior INC. | $150.31 | 2019-2025 | Sublocade, Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $135.78 | 2023-2025 | Caplyta |
| Lundbeck LLC | $107.41 | 2020-2024 | Rexulti |
| Almatica Pharma LLC | $66.74 | 2022-2025 | Loreev Xr |
| Supernus Pharmaceuticals, INC. | $58.57 | 2021-2022 | |
| Axsome Therapeutics, INC. | $46.12 | 2025 | Auvelity |
| Collegium Pharmaceutical, INC. | $40.10 | 2025 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $28.99 | 2019 | |
| Brainsway USA INC | $26.32 | 2024 | Brainsway Deep Tms System |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $18.33 | 2019 | |
| Tris Pharma INC | $16.96 | 2019 | |
| Allergan, INC. | $15.04 | 2019 | |
| Shire North American Group INC | $13.83 | 2019 | |
| Neos Therapeutics, LP | $12.52 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfredo Aguirre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.